We are pleased to announce that UpTides Bio has joined the Peptide Drug Hunting Consortium’s (PDHC) Entrepreneurial Business Network. This exciting collaboration connects us with a diverse community of science experts and business leaders and we are looking forward to engaging with this exceptional group of entrepreneurs and scientists, dedicated to advancing peptide-based therapeutics and applications.
The PDHC, led by Founding President Dr. Tomi K. Sawyer, is building a dynamic ecosystem connecting scientific innovation and commercial development in the peptide space. The consortium aims to create a hub where innovators and service providers can collaborate. This vision of building a network that connects experts from life sciences companies aligns perfectly with our mission at UpTides Bio. Together, we can truly empower breakthrough healthcare innovation and make a difference in the future discovery, development and ultimately success of peptide drugs worldwide.
As specialists in the redesign of peptides and, our team at UpTides Bio has valuable expertise in developing novel compounds. Our participation in this network is another step in creating innovative molecules that make a meaningful difference for people.
Dr. Martina Diekmann, UpTides Bio’s visionary CEO, has earned a spotlight in the PDHC’s member highlight—recognition that celebrates her transformative approach in the peptides industry. Blending two decades of expertise from medicinal chemistry laboratories to executive boardrooms, Dr. Diekmann brings a rare dual perspective to the consortium’s ambitious initiatives. Her unique science-meets-business mindset will fuel collaborative partnerships within this dynamic network.
This strategic alliance is a catalyst in our journey to revolutionize both healthcare and beauty landscapes through precisely engineered peptide solutions. Where science transcends beauty, innovation meets purpose.
